Connect with us


Sight Sciences Plans $240M IPO

The company’s valuation will be more than $1B.




MENLO PARK, CA — Sight Sciences Inc., a medical device company targeting eye diseases, announced the pricing of its initial public offering of 10,000,000 shares of common stock at a public offering price of $24 per share.

All shares of common stock are being offered for total gross proceeds of $240 million, before deducting underwriting discounts and commissions and offering expenses. In addition, Sight Sciences has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.

Sight Sciences’s stock is expected to begin trading on the Nasdaq Global Market on July 15 under the ticker symbol “SGHT.” The offering is expected to close on July 19, subject to customary closing conditions.

Sight Science had originally looked to raise $160.54 million, MarketWatch reports.

With the increase in price and number of shares, the company’s valuation will be more than $1 billion.



Meet the Next Generation of Smart Glasses

Ray-Ban Meta is now available with a full range of lenses, as a complete pair or edged lens. Prescription orders eligible through select insurance providers, including Eyemed and private pay. The Ray-Ban Meta collection combines iconic design with cutting-edge technology. Capture life’s best moments and livestream to Facebook and Instagram with an upgraded 12 MP camera and five-mic system. Stay connected with hands-free calls and messages. Listen to your favorite tracks through built-in speakers. Spark your creativity, get information and control your glasses with your voice – powered by Meta AI. All while keeping your phone in your pocket. For more information, visit here.

Promoted Headlines





Get the most important news and business ideas for eyecare professionals every weekday from INVISION.



Most Popular